Background: Recruitment and retention of participants are critical to the success of a randomised controlled trial. Gaining the views of potential trial participants who decline to enter a trial and of trial participants who stop the trial treatment is important and can help to improve study processes. Limited research on these issues has been conducted on healthy individuals recruited for prevention trials in the community.

Methods: Semi-structured interviews with people who were eligible but had declined to participate in the Aspirin for Asymptomatic Atherosclerosis (AAA) trial (N = 11), and AAA trial participants who had stopped taking the trial medication (N = 11). A focus group with further participants who had stopped taking the trial medication (N = 6). (Total participants N = 28).

Results: Explanations for declining to participate could be divided into two groups: the first group were characterised by a lack of necessity to participate and a tendency to prioritise other largely mundane problems. The second group's concern was with a high level of perceived risk from participating.Explanations for stopping trial medication fell into four categories: side effects attributed to the trial medication; starting on aspirin or medication contraindicating to aspirin; experiencing an outcome event, and changing one's mind.

Conclusions: These results indicate that when planning trials (especially in preventive medicine) particular attention should be given to designing appropriate recruitment materials and processes that fully inform potential recruits of the risks and benefits of participation.

Trial Registration: ISRCTN66587262.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024954PMC
http://dx.doi.org/10.1186/1745-6215-12-7DOI Listing

Publication Analysis

Top Keywords

trial medication
16
trial
12
trial participants
12
randomised controlled
8
controlled trial
8
aaa trial
8
participants stopped
8
stopped trial
8
participants
6
medication
5

Similar Publications

Introduction: Parkinson's disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of PD.

Areas Covered: A phase 2 clinical trial of lixisenatide, a GLP-1 receptor agonist, in the early stages of PD.

View Article and Find Full Text PDF

Tumors are complex ecosystems of interacting cell types. The concept of cancer hallmarks distills this complexity into underlying principles that govern tumor growth. Here, we explore the spatial distribution of cancer hallmarks across 63 primary untreated tumors from 10 cancer types using spatial transcriptomics.

View Article and Find Full Text PDF

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies.

Discov Oncol

January 2025

Division of Hematology/Oncology, The University of Texas Health Sciences Center at Houston, McGovern Medical School, 6431 Fannin Street, MSB 5.216, Houston, TX, 77030, USA.

The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment.

View Article and Find Full Text PDF

Efficacy of Chewing Xylitol Gum on Restoring Postoperative Bowel Activity After Laparoscopic Cholecystectomy: A Three-arm Randomized Controlled Trial.

J Perianesth Nurs

January 2025

Medical Faculty, Department of Anesthesia and Reanimation, Giresun Üniversitesi, Giresun, Türkiye. Electronic address:

Purpose: The aim in the present study was to evaluate the effects of chewing postoperative xylitol gum on gastrointestinal functional recovery after laparoscopic cholecystectomy.

Design: A three-arm randomized controlled trial.

Methods: After a baseline assessment, participants were randomly assigned in three groups.

View Article and Find Full Text PDF

Background: Malnutrition is common with esophagogastric cancers and is associated with negative outcomes. We aimed to evaluate if immunonutrition during neoadjuvant treatment improves patient's health-related quality of life (HRQOL) and reduces postoperative morbidity and toxicities during neoadjuvant treatment.

Methods: A multicenter double-blind randomized controlled trial (RCT) was undertaken.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!